Tevogen Bio Holdings Inc. (NASDAQ:TVGN – Get Free Report)’s share price traded down 8.9% during trading on Tuesday . The stock traded as low as $1.36 and last traded at $1.53. 5,120,275 shares were traded during mid-day trading, a decline of 6% from the average session volume of 5,419,914 shares. The stock had previously closed at $1.68.
Tevogen Bio Price Performance
The company has a 50-day moving average price of $1.21 and a 200 day moving average price of $1.01.
Institutional Investors Weigh In On Tevogen Bio
An institutional investor recently bought a new position in Tevogen Bio stock. China Universal Asset Management Co. Ltd. bought a new position in Tevogen Bio Holdings Inc. (NASDAQ:TVGN – Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 37,117 shares of the company’s stock, valued at approximately $38,000.
Tevogen Bio Company Profile
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
Further Reading
- Five stocks we like better than Tevogen Bio
- Following Congress Stock Trades
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- What Does the Future Hold for Eli Lilly?
- 5 discounted opportunities for dividend growth investors
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.